New Chemo-Free combo aims to shrink lung tumors before surgery

This study tests a new approach for people with early-stage lung cancer who cannot or do not want chemotherapy. Before surgery, patients receive a short course of focused radiation (SBRT), an immunotherapy drug (tislelizumab), and an antiangiogenic drug (anlotinib) to shrink the tumor. The goal is to see if this chemo-free combination can eliminate all cancer cells in the removed tissue while causing fewer side effects than standard chemotherapy. About 39 adults with stage IB to IIIB non-small cell lung cancer that does not have certain gene mutations will participate.